Product Code: ETC6183360 | Publication Date: Sep 2024 | Updated Date: Apr 2025 | Product Type: Market Research Report | |
Publisher: 6Wresearch | Author: Vasudha | No. of Pages: 75 | No. of Figures: 35 | No. of Tables: 20 |
The IBS market in Australia is expanding due to the rising prevalence of gastrointestinal disorders and increasing awareness of digestive health. Diagnosis rates have improved due to better diagnostic tools and growing awareness among the general population. Treatments include a combination of dietary management, lifestyle changes, and medications such as antispasmodics and laxatives. The market is characterized by a growing interest in probiotics, natural remedies, and gut health solutions, driven by consumer preferences for holistic wellness approaches.
The IBS market in Australia is showing a rising trend due to growing public awareness of gastrointestinal health and an increase in the diagnosed cases of IBS. Consumers are turning to both conventional pharmaceuticals and natural or probiotic-based therapies. Lifestyle and dietary management solutions are also becoming increasingly popular. The market is further supported by increased funding in digestive health research and the broader acceptance of gut health as a key component of overall wellness.
In the Australia irritable bowel syndrome (IBS) market, challenges arise from the complexity of accurately diagnosing IBS, given its overlapping symptoms with other gastrointestinal disorders. Limited effective treatment options and the high variability of individual patient responses to therapies also constrain market growth.
Investors in the IBS market can leverage the increasing prevalence of gastrointestinal disorders linked to lifestyle, stress, and dietary changes. There`s a rising demand for personalized treatment solutions, probiotic formulations, and gut health supplements. Opportunities exist in diagnostics, functional foods, and telemedicine services tailored for IBS management. Moreover, growing awareness and destigmatization of digestive health issues open doors for consumer education and digital health platforms.
The Australian government`s focus on gut health research funding through institutions like the NHMRC (National Health and Medical Research Council) benefits the IBS market. Policies promoting dietary education and the regulation of pharmaceutical treatments for IBS also play a critical role.
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 Australia Irritable Bowel Syndrome (IBS) Market Overview |
3.1 Australia Country Macro Economic Indicators |
3.2 Australia Irritable Bowel Syndrome (IBS) Market Revenues & Volume, 2021 & 2031F |
3.3 Australia Irritable Bowel Syndrome (IBS) Market - Industry Life Cycle |
3.4 Australia Irritable Bowel Syndrome (IBS) Market - Porter's Five Forces |
3.5 Australia Irritable Bowel Syndrome (IBS) Market Revenues & Volume Share, By Drug Type, 2021 & 2031F |
3.6 Australia Irritable Bowel Syndrome (IBS) Market Revenues & Volume Share, By Medical Condition, 2021 & 2031F |
3.7 Australia Irritable Bowel Syndrome (IBS) Market Revenues & Volume Share, By Distribution Channel, 2021 & 2031F |
3.8 Australia Irritable Bowel Syndrome (IBS) Market Revenues & Volume Share, By End-Users, 2021 & 2031F |
4 Australia Irritable Bowel Syndrome (IBS) Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.3 Market Restraints |
5 Australia Irritable Bowel Syndrome (IBS) Market Trends |
6 Australia Irritable Bowel Syndrome (IBS) Market, By Types |
6.1 Australia Irritable Bowel Syndrome (IBS) Market, By Drug Type |
6.1.1 Overview and Analysis |
6.1.2 Australia Irritable Bowel Syndrome (IBS) Market Revenues & Volume, By Drug Type, 2021- 2031F |
6.1.3 Australia Irritable Bowel Syndrome (IBS) Market Revenues & Volume, By Lubiprostone, 2021- 2031F |
6.1.4 Australia Irritable Bowel Syndrome (IBS) Market Revenues & Volume, By Linaclotide, 2021- 2031F |
6.1.5 Australia Irritable Bowel Syndrome (IBS) Market Revenues & Volume, By Eluxadoline, 2021- 2031F |
6.1.6 Australia Irritable Bowel Syndrome (IBS) Market Revenues & Volume, By Rifaximin, 2021- 2031F |
6.1.7 Australia Irritable Bowel Syndrome (IBS) Market Revenues & Volume, By Alosetron, 2021- 2031F |
6.1.8 Australia Irritable Bowel Syndrome (IBS) Market Revenues & Volume, By Others, 2021- 2031F |
6.2 Australia Irritable Bowel Syndrome (IBS) Market, By Medical Condition |
6.2.1 Overview and Analysis |
6.2.2 Australia Irritable Bowel Syndrome (IBS) Market Revenues & Volume, By IBS-Constipation, 2021- 2031F |
6.2.3 Australia Irritable Bowel Syndrome (IBS) Market Revenues & Volume, By IBS-diarrhea, 2021- 2031F |
6.2.4 Australia Irritable Bowel Syndrome (IBS) Market Revenues & Volume, By Mixed, 2021- 2031F |
6.3 Australia Irritable Bowel Syndrome (IBS) Market, By Distribution Channel |
6.3.1 Overview and Analysis |
6.3.2 Australia Irritable Bowel Syndrome (IBS) Market Revenues & Volume, By Hospital Pharmacies, 2021- 2031F |
6.3.3 Australia Irritable Bowel Syndrome (IBS) Market Revenues & Volume, By Online Pharmacies, 2021- 2031F |
6.3.4 Australia Irritable Bowel Syndrome (IBS) Market Revenues & Volume, By Retail Pharmacies, 2021- 2031F |
6.4 Australia Irritable Bowel Syndrome (IBS) Market, By End-Users |
6.4.1 Overview and Analysis |
6.4.2 Australia Irritable Bowel Syndrome (IBS) Market Revenues & Volume, By Hospitals, 2021- 2031F |
6.4.3 Australia Irritable Bowel Syndrome (IBS) Market Revenues & Volume, By Clinics, 2021- 2031F |
6.4.4 Australia Irritable Bowel Syndrome (IBS) Market Revenues & Volume, By Homecare Settings, 2021- 2031F |
7 Australia Irritable Bowel Syndrome (IBS) Market Import-Export Trade Statistics |
7.1 Australia Irritable Bowel Syndrome (IBS) Market Export to Major Countries |
7.2 Australia Irritable Bowel Syndrome (IBS) Market Imports from Major Countries |
8 Australia Irritable Bowel Syndrome (IBS) Market Key Performance Indicators |
9 Australia Irritable Bowel Syndrome (IBS) Market - Opportunity Assessment |
9.1 Australia Irritable Bowel Syndrome (IBS) Market Opportunity Assessment, By Drug Type, 2021 & 2031F |
9.2 Australia Irritable Bowel Syndrome (IBS) Market Opportunity Assessment, By Medical Condition, 2021 & 2031F |
9.3 Australia Irritable Bowel Syndrome (IBS) Market Opportunity Assessment, By Distribution Channel, 2021 & 2031F |
9.4 Australia Irritable Bowel Syndrome (IBS) Market Opportunity Assessment, By End-Users, 2021 & 2031F |
10 Australia Irritable Bowel Syndrome (IBS) Market - Competitive Landscape |
10.1 Australia Irritable Bowel Syndrome (IBS) Market Revenue Share, By Companies, 2024 |
10.2 Australia Irritable Bowel Syndrome (IBS) Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |